To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

August 07, 2018

Today's Rundown

Featured Story

Spark slides on hemophilia A data, aims for phase 3

Spark Therapeutics’ hemophilia A gene therapy reduced bleeding by 97% in a phase 1/2 trial but sent one patient to the hospital, leading the biotech's stock to dip about 30% before the market opened.

Top Stories

U.K. commits to adopt EU trial regulation, minimize divergence after Brexit

The U.K. regulatory agency has detailed how it expects Brexit to affect its clinical trial regulations. Officials reiterated their intent for the U.K. to implement the incoming European Union Clinical Trials Regulation and expanded on the long-term effects of Brexit on research approval processes.

With patisiran launch in its sights, Alnylam plots a major hiring spree

Alnylam’s first drug approval could come any day now, and the company is bulking up to get ready—in more ways than one. The RNAi-focused biotech is expanding in Cambridge's Kendall Square and going on a hiring binge that will double its roster.

FDA notes Paratek antibiotic’s noninferiority as it heads to AdComm vote

Paratek Pharmaceuticals’ first drug, and the first in a new class of broad-spectrum antibiotics called aminomethylcyclines, has shown to be noninferior to current regimens for bacterial pneumonia and skin infections, FDA reviewers wrote ahead of an Aug. 8 advisory committee meeting.

Akouos raises $50M to take hearing loss gene therapy into humans

Akouos has raised $50 million to take a gene therapy treatment for hearing loss into the clinic. The Boston-based biotech unveiled the series A round alongside the appointment of a Spark Therapeutics co-founder and other organizational changes.

Ironwood abandons deal with AstraZeneca for lesinurad, once hoped to be a gout blockbuster

Ironwood Pharmaceuticals has decided to walk away from its 2016 deal to license AstraZeneca’s billion-dollar gout treatment lesinurad in the U.S., following poor market performance of the drug, as Ironwood continues its march toward splitting into two separate public companies next year.

Cha-ching: Small biotechs write some of America's biggest paychecks

Infinity, Savara and Sarepta are among the highest-paying companies in the U.S., a new report reveals. But the gap between CEO compensation and the pay the average employee brings home remains vast.

Resources

[Whitepaper] Getting to First-in-Human Clinical Trials: A Make-or-Break Milestone for Small Biopharmas

“Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market faster. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for these cash-strapped companies whose hopes hinge upon one or two molecules. Read how CDMOs are responding to this pressure.

[Whitepaper] HOW TO POSITION YOUR PATIENT SUPPORT PROGRAM FOR SUCCESS

When was the last time your patient support program perfectly aligned with the patient journey, solving all the critical gaps in positioning your brand for success? Follow the 3-D approach to your solution design, and you will achieve a better outcome for your patients.

[Whitepaper] Avoid Enrollment Pitfalls: Find Your Best-fit Clinical Trial Sites

Selecting the right sites is the most crucial decision you’ll make in your next clinical trial, and the single most important factor to consider in selecting a site is whether or not it can meet its enrollment goals.

[Survey] Industry Report: Findings from the 2018 Unified Clinical Operations Survey

Industry Research: See new results from one of the industry's largest, global clinical operations surveys.

[Whitepaper] How early planning and a unified data platform can cut trial timelines and cost.

Accelerate Clinical Research as Study Complexity Grows

[Whitepaper] Building the Business Case for RIM Transformation

Ready to modernize your RIM environment? Secure buy-in with these tips.

[Whitepaper] Rise in Targeted Therapies Drives Needs for Small Volume Manufacturing

Biologics, orphan drugs, and precision medicine are on the rise, and that means some big changes for drug development and manufacturing companies. What should pharma companies look for when navigating this new era of small-volume manufacturing? Here are some ideas to consider when developing a new manufacturing strategy.

[Whitepaper] eClinical Landscape Study - CRO Report from Tufts Center for the Study of Drug Development

See results from the Tufts eClinical Landscape Study – CRO Report on current data management practices, goals, and challenges for contract research organizations (CROs).

[eLearning] BIOAVAILABILITY 101

Develop a basic understanding of principles and concepts of bioavailability of oral drugs.

Events

.